Abstract
Dyslipidemia is arguably the leading contributing factor in the development of atherosclerosis and subsequent cardiovascular disease in obesity. The link between obesity and dyslipidemia is complex. Recently, the role of brown fat and its potential as a therapeutic target for weight loss have been of interest. Given the rising prevalence of obesity and dyslipidemia globally, research has focused on the optimal monitoring of lipids. Recent advances suggest a move away from monitoring low-density lipoprotein and more toward monitoring non–high-density lipoprotein and apolipoprotein B, which give a better picture of the true atherogenic burden. Methods for weight loss have been well described and include diet, exercise, and pharmaceutical and surgical options. This chapter explores (1) how free fatty acids, body fat distribution, insulin resistance, and brown fat influence the development of dyslipidemia in obesity; (2) the benefits, practicalities, and interpretation of different lipid biomarkers in obesity; and (3) several methods for weight loss, their individual efficacy, and their effect on lipid profile.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
